Recent Quotes
My Watchlist
Indicators
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MoonLake Immunotherapeutics - Class A Ordinary Shares (NQ:MLTX)

17.16 -0.54 (-3.02%)
Streaming Delayed Price Updated: 2:24 PM EDT, May 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 522,029
Open 17.50
Bid (Size) 17.16 (200)
Ask (Size) 17.17 (100)
Prev. Close 17.70
Today's Range 16.88 - 17.61
52wk Range 5.950 - 62.75
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
The CEO of MoonLake Immunotherapeutics Dumped Shares Worth $2.8 Million. Should Investors Avoid the Stock? ↗
Focused on novel immunotherapies for inflammatory diseases, this biotech firm reported significant insider selling in its latest filing. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Fund BVF Trims MoonLake Stake, Sells $63M in Shares ↗
Focused on immunology therapies, this clinical-stage biotech reported significant insider selling amid a challenging year for the stock. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
+43.6%
+43.6%
1 Month
+1.1%
+1.1%
3 Month
+14.2%
+14.2%
6 Month
+62.1%
+62.1%
1 Year
-56.3%
-56.3%

More News

Read More
News headline image
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? ↗
Via The Motley Fool
Topics Regulatory Compliance
MLTX Stock Extends Rally As FDA Feedback Spurs Bullish Brokerage Action – Retail Speculates On Potential M&A Conversations ↗
Via Stocktwits
News headline image
Structure Therapeutics Stock Soars Over 200% as One Fund Adds to a $242 Million Position ↗
Via The Motley Fool
News headline image
Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Disc Medicine Stock Is Swinging, but This Fund's New $52 Million Bet Shows Conviction ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Nasdaq, S&P 500 Futures Fall On Tariff, Iran Tensions: Why NVDA, NFLX, HON, IBRX, MLTX Are On Traders' Radar Today ↗
Via Stocktwits
Topics Artificial Intelligence ETFs Government
News headline image
MLTX Stock Jumps Over 10% Overnight As Spine Drug Trial Win Sets Stage For Investor Day Showdown ↗
Via Stocktwits
News headline image
MLTX Stock Heads Into Investor Day With FDA Momentum – What Traders Should Watch Next Week ↗
Via Stocktwits
News headline image
Nasdaq, S&P 500 Futures Edge Higher Ahead Of Fed Minutes: Why NVDA, TSLA, AAPL, APLD, PANW Are On Traders' Radar Today ↗
Via Stocktwits
Topics ETFs Economy Lawsuit
News headline image
MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites ↗
Via Stocktwits
News headline image
MLTX Stock Gains As Retail Eyes Buyout From Big Pharma, Upcoming Investor Day Event ↗
Via Stocktwits
Topics Intellectual Property
News headline image
ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer
From ImageneBio, Inc.
Via GlobeNewswire
News headline image
BioTech Breakout: MoonLake Up 30% On FDA Wins ↗
Via MarketBeat
News headline image
MLTX Stock Erases Most Of 2025 Loses As Wall Street, Retail Bets On FDA Feedback For Sonelokimab ↗
Via Stocktwits
News headline image
MoonLake Immunotherapeutics Surges as FDA "De-Risks" Sonelokimab, Reigniting Multi-Billion Dollar Takeover Speculation
Via MarketMinute
Topics Intellectual Property
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
Why Did MLTX Stock Jump 45% In Pre-Market Today? ↗
Via Stocktwits
Get insights into the top gainers and losers of Thursday's pre-market session. ↗
Via Chartmill
News headline image
MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX
From DJS Law Group
Via Business Wire
News headline image
MOONLAKE DECEMBER 15th DEADLINE: Bragar Eagel & Squire, P.C. Urgently Reminds MoonLake Immunotherapeutics Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
MOONLAKE CLASS ACTION DEADLINE: Bragar Eagel & Squire, P.C. Urgently Reminds MoonLake Immunotherapeutics Investors to Contact the Firm Before December 15th
From Bragar Eagel & Squire
Via GlobeNewswire

Frequently Asked Questions

Is MoonLake Immunotherapeutics - Class A Ordinary Shares publicly traded?
Yes, MoonLake Immunotherapeutics - Class A Ordinary Shares is publicly traded.
What exchange does MoonLake Immunotherapeutics - Class A Ordinary Shares trade on?
MoonLake Immunotherapeutics - Class A Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for MoonLake Immunotherapeutics - Class A Ordinary Shares?
The ticker symbol for MoonLake Immunotherapeutics - Class A Ordinary Shares is MLTX on the Nasdaq Stock Market
What is the current price of MoonLake Immunotherapeutics - Class A Ordinary Shares?
The current price of MoonLake Immunotherapeutics - Class A Ordinary Shares is 17.16
When was MoonLake Immunotherapeutics - Class A Ordinary Shares last traded?
The last trade of MoonLake Immunotherapeutics - Class A Ordinary Shares was at 05/07/26 02:24 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.